CG Oncology, Inc. (CGON) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$85.55M*; Operating income -$86.40M; Depreciation and amortization $850.00K*.
- 2026-03-31: Basis Reported; EBITDA -$65.55M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$47.85M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$50.71M*; Operating income -$51.13M; Depreciation and amortization $416.00K*.
Complete source-backed ebitda history.
- Available history
- 2023-03-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$85.55M* | -$86.40M | $850.00K* | (m) | (m) | $468.00K* | -$46.41M* | (m) | $54.66M | (m) | (m) |
|---|
| 2026-03-31 | Reported | -$65.55M | (m) | (m) | (m) | -6052.45% | $304.00K | -$56.94M | (m) | $43.73M | (m) | (m) |
|---|
| 2025-12-31 | Reported | -$47.85M | (m) | (m) | (m) | -2060.77% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$50.71M* | -$51.13M | $416.00K* | (m) | (m) | $97.00K* | -$38.89M* | (m) | $27.88M | (m) | (m) |
|---|
| 2025-06-30 | Reported | -$48.59M* | -$48.74M | $156.00K* | (m) | (m) | $14.00K* | -$27.96M* | (m) | $31.33M | (m) | (m) |
|---|
| 2025-03-31 | Reported | -$42.18M | (m) | (m) | (m) | -81115.38% | $16.00K | -$29.28M | (m) | $27.47M | (m) | (m) |
|---|
| 2024-12-31 | Reported | -$38.05M | (m) | (m) | (m) | -8344.08% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$28.27M* | -$28.30M | $21.00K* | (m) | (m) | -$1.00K* | -$15.92M* | (m) | $19.62M | (m) | (m) |
|---|
| 2024-06-30 | Reported | -$25.85M* | -$25.85M | $7.00K* | (m) | (m) | $14.00K* | -$16.12M* | (m) | $18.47M | (m) | (m) |
|---|
| 2024-03-31 | Reported | -$22.47M | (m) | (m) | (m) | -4246.69% | $12.00K | -$26.01M | (m) | $17.21M | (m) | (m) |
|---|
| 2023-12-31 | Reported | -$19.35M | (m) | (m) | (m) | -1935100.00% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$14.04M* | -$14.04M | $5.00K* | (m) | (m) | (m) | -$12.26M* | (m) | $11.73M | (m) | (m) |
|---|
| 2023-06-30 | Reported | -$12.32M* | -$12.33M | $4.00K* | (m) | (m) | (m) | -$10.79M* | (m) | $9.83M | (m) | (m) |
|---|
| 2023-03-31 | Reported | -$9.72M | (m) | (m) | (m) | -5008.76% | (m) | -$7.99M | (m) | $7.84M | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$189.33M | (m) | (m) | (m) | -4686.36% | $134.00K | -$132.35M | (m) | $116.64M | (m) | -$270.00K |
|---|
| 2024-12-31 | Reported | -$114.63M | (m) | (m) | (m) | -10064.44% | $234.00K | -$78.71M | (m) | $82.10M | (m) | $1.00K |
|---|
| 2023-12-31 | Reported | -$55.43M | (m) | (m) | (m) | -27172.55% | (m) | -$45.68M | (m) | $45.75M | (m) | $1.00K |
|---|